PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES

被引：2
|
作者：
Rosell, R. [1 ]
Gettinger, S. [2 ]
Bazhenova, L. A. [3 ]
Langer, C. J. [4 ]
Salgia, R. [5 ]
Gold, K. [6 ]
Shaw, A. T. [7 ]
Dorer, D. J. [8 ]
Kerstein, D. [9 ]
Camidge, D. R. [10 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Serv, Badalona, Spain
[2] Yale Univ, Sch Med Med Oncol, Thorac Oncol Program, New Haven, CT USA
[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Chicago, Med Ctr, Thorac Oncol, Chicago, IL 60637 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[8] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA
[9] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA
[10] Univ Colorado, Ctr Canc, Thorac Oncol, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Kerstein, David
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [5] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [6] Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases
    Gettinger, S. N.
    Bazhenova, L.
    Salgia, R.
    Langer, C. J.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, D. R.
    LUNG CANCER, 2015, 87 : S32 - S32
  • [7] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Conlan, Maureen G.
    Kerstein, David
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239
  • [9] Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
    Gettinger, S. N.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, D. R.
    LUNG CANCER, 2016, 91 : S20 - S21
  • [10] Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non -small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
    Kim, Edward S.
    Ou, Sai-Hong Ignatius
    Barlesi, Fabrice
    Mok, Tony S. K.
    Ahn, Myung-Ju
    Bunn, Veronica
    Zhang, Pingkuan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345